Red blood cell transfusion in the critically ill patient

Christophe Lelubre and Jean-Louis Vincent*

Abstract
Red blood cell (RBC) transfusion is a common intervention in intensive care unit (ICU) patients. Anemia is frequent in this population and is associated with poor outcomes, especially in patients with ischemic heart disease. Although blood transfusions are generally given to improve tissue oxygenation, they do not systematically increase oxygen consumption and effects on oxygen delivery are not always very impressive. Blood transfusion may be lifesaving in some circumstances, but many studies have reported increased morbidity and mortality in transfused patients. This review focuses on some important aspects of RBC transfusion in the ICU, including physiologic considerations, a brief description of serious infectious and noninfectious hazards of transfusion, and the effects of RBC storage lesions. Emphasis is placed on the importance of personalizing blood transfusion according to physiological endpoints rather than arbitrary thresholds.

Introduction
Red blood cell (RBC) transfusion is commonly required in critically ill patients. Several recent, observational, multicenter studies reported that approximately one third of critically ill patients received a blood transfusion at one time or another during their stay in the intensive care unit (ICU) (Table 1). Because of the frequent use of this intervention, it is important for the ICU physician to be aware of recent developments in this continuously evolving field of medicine. In this narrative review, we consider some key aspects of transfusion medicine in the ICU, focusing on aspects relevant to the critically ill patient, including prevalence and reasons for blood transfusion, epidemiology and etiology of anemia in these patients, pathophysiological considerations on tolerance to anemia, and efficacy of RBC transfusion. Safety concerns, including questions of RBC storage and leukoreduction, are then discussed, followed by a proposal for an integrated approach to transfusion decisions and a discussion on economic aspects and alternatives to blood transfusion.

Epidemiology of anemia and red blood cell transfusion in the ICU
Anemia is common in ICU patients and appears early in the ICU course [1]. In an observational, multicenter, cohort study in Scotland, 25% of patients admitted to the ICU had a hemoglobin level < 9 g/dl [2]. Similar results were reported in the ABC study [3], in which 29% of patients had a hemoglobin concentration < 10 g/dl on admission. Even in nonbleeding ICU patients, hemoglobin levels tend to decrease early [3]. This decrease is more pronounced in septic than in nonseptic patients [4], at least in part because of their inflammatory response; more frequent blood sampling may also contribute.

Interestingly, anemia and the need to restore adequate oxygen delivery (DO₂) are the most common indications for transfusion, rather than acute bleeding [3,5-10]. Anemia in the critically ill patient is a multifactorial phenomenon that has been compared to the so-called “anemia of chronic illness” [11]. Apart from evident causes of anemia, such as primary blood losses (e.g., trauma, surgery, gastrointestinal bleeding), multiple other etiologies contribute to its pathophysiology and often coexist in the same patient [11]. These include blood losses related to minor procedures or phlebotomy, and hemodilution secondary to fluid resuscitation. Some studies have suggested that blood sampling may average as much as 40 ml/day [3,4], but the amount of blood required may decrease with technological developments in analytic methods. Other mechanisms for anemia include an inflammatory response with blunted erythropoietin (EPO) production, abnormalities in iron...
| Author          | Year study was conducted | Country/region          | No. of patients and number of ICUs | Percentage transfused in ICU | Pretransfusion hemoglobin level | Mean no. of units transfused in ICU | Mean age of blood (days) |
|-----------------|--------------------------|-------------------------|-----------------------------------|-----------------------------|---------------------------------|-----------------------------------|-------------------------|
| Hebert et al.   | 1993                     | Canada                  | 5,298 patients in 6 ICUs         | 25.0                        | Mean: 8.6 ± 1.3 g/dl            | NS                                | NS                      |
| Vincent et al.  | 1999                     | Western Europe          | 3,534 patients in 146 ICUs       | 37.0                        | Mean: 8.4 ± 1.3 g/dl            | 4.8 ± 5.2                         | 16.2 ± 6.7              |
| Rao et al.      | 1999                     | UK                      | 1,247 patients in 9 ICUs         | 53.0                        | Median: 8.5 (IQR: 7.9-9) g/dl   | 6.75 (hemorrhage) and 4.25 (anemia) | NS                      |
| Corwin et al.   | 2000 - 2001              | USA                     | 4,892 patients in 284 ICUs       | 44.0                        | Mean: 8.6 ± 1.7 g/dl            | 4.6 ± 4.9                         | 21 ± 11.4               |
| Walsh et al.    | 2001                     | UK (Scotland)           | 1,023 patients in 10 ICUs        | 39.5                        | Median: 7.8 (7.3-8.5) g/dl      | Mean: 1.87 unit/ICU admission    | NS                      |
| French et al.   | 2001                     | Australia and New Zealand | 1,808 patients in 18 ICUs       | 19.8                        | Median: 8.2 (range: 4.4-18.7) g/dl | Mean: 4.18                      | NS                      |
| Vincent et al.  | 2002                     | Western and Eastern Europe | 3,147 patients in 198 ICUs     | 33.0                        | Median: 8.2 g/dl                | 50 ± 5.8                         | NS                      |
| Westbrook et al.| 2008                     | Australia and New Zealand | 5,128 patients in 47 ICUs       | 14.7                        | Mean: 7.7 g/dl                  | Median: 2 (IQR: 1-4)              | Median: 14 (IQR: 9.5-21.5) |

ICU intensive care unit; NS not specified; IQR interquartile range
metabolism, and altered proliferation and differentiation of medullar erythroid precursors [11]. As a consequence, RBC deformability is decreased [12], whereas RBC adherence to the endothelium is increased, especially in septic patients, potentially leading to microcirculatory impairment and tissue hypoxia [13].

**Tolerance to anemia in healthy subjects and in the critically ill patient**

Tolerance to anemia is highly dependent on the volume status of the patient, physiological reserve, and the dynamics of the anemia (for example, chronic, such as the anemia of sepsis, versus acute, such as hemorrhagic conditions). Normovolemic anemia is better tolerated than anemia in hypovolemic states (e.g., acute bleeding in trauma patients or surgery) in which cardiac output acutely decreases. In healthy subjects submitted to normovolemic hemodilution, cardiac output increases because of decreased blood viscosity (especially relevant in severe anemia) and increased adrenergic response, allowing tachycardia and increased myocardial contractility. Other phenomena include blood flow redistribution (to heart and brain) and an increased oxygen extraction ratio (reflected by a decrease in mixed venous saturation [SvO2]). These mechanisms allow healthy humans to tolerate severe degrees of normovolemic anemia [14,15], although side effects, such as arrhythmias or ST changes, can be observed in extreme cases [16,17]. The myocardium is the organ at risk in cases of acute anemia in which both tachycardia and increased ventricle contractility may increase myocardial oxygen demand. Because myocardial oxygen extraction is already almost maximal at rest, every increase in myocardial oxygen demand must be accompanied by increased coronary blood flow [18]. This can become problematic in patients with stenotic coronary arteries especially when tachycardia is present, which can decrease diastole-dependent left ventricle perfusion.

Therefore, in critically ill patients, especially those with heart failure or coronary artery disease (CAD), the myocardium may not tolerate such low hemoglobin levels [19]. In acute myocardial infarction, anemia may worsen myocardial ischemia, generate arrhythmias, and potentially increase infarct size [20]. In patients with acute coronary syndrome or heart failure, anemia increases morbidity and mortality [21,22]. For these reasons, patients with cardiac problems should be managed with a more liberal approach to transfusion than other patients [23,24].

**Purpose and efficacy of blood transfusion**

The primary purpose of blood transfusion is to increase DO2, which is determined by cardiac output and arterial content of oxygen, the latter being dependent on the hemoglobin level. Hence, blood transfusions can, theoretically at least, limit tissue hypoxia [13,25,26]. But does this really happen in clinical practice? It is obvious that RBC transfusions can be lifesaving in situations of acute severe anemia or in bleeding patients in whom RBC administration can increase both oxygen arterial content and cardiac output. However, in the absence of bleeding, the increase in hemoglobin concentration could very well be offset by a decrease in cardiac output because of the increase in blood viscosity associated with a decreased sympathetic response [27,28]. DO2 has been shown to increase following RBC transfusion in numerous studies [26], but not in all [29].

The effects of RBC transfusion on the relationship between DO2 and oxygen uptake (VO2) are even more difficult to predict. Some studies reported that VO2 increased following RBC transfusion, whereas others did not [26], and variable effects have been reported on tissue perfusion as assessed by gastric mucosal pH or near-infrared spectroscopy (NIRS) [30]. The reasons for these contradictory results lie primarily in the degree of severity of hypoxia preceding the RBC transfusion [31], which influences the dependency of VO2 on DO2. Methodological problems (imprecision in determination of VO2, assessment of global VO2 instead of regional VO2, poor correlation between systemic oxygenation parameters, and oxygenation in the microcirculation [13]) also may contribute to these discrepancies [31].

**Safety concerns of blood transfusions**

**Impact on outcome**

Red blood cell transfusions have been associated with worse outcomes in several populations of patients, including critically ill patients. In a recent systematic review of 45 observational studies reporting the impact of transfusions on patient outcome (mortality, infections, acute respiratory distress syndrome [ARDS]) in populations of trauma, general surgery, orthopedic surgery, acute coronary syndrome, and ICU patients, Marik and Corwin [32] identified RBC transfusion as an independent predictor of death (pooled odds ratio (OR) from 12 studies, 1.7; 95% confidence interval (CI), 1.4-1.9), infectious complications (pooled OR from 9 studies, 1.8; 95% CI, 1.5-2.2), and ARDS (pooled OR from 6 studies, 2.5; 95% CI, 1.6-3.3). In ICU patients, the three studies included in the review (ABC study [3], CRIT study [5], and a study by Gong et al. [33]) consistently showed a statistically significant association of RBC transfusion with mortality.

On the other hand, analysis of data from a multicenter, prospective, observational study of 3,147 patients in 198 European ICUs (the SOAP study) indicated that
blood transfusions were not associated with increased mortality by multivariate analysis or propensity matching [34]. In contrast, an extended Cox proportional hazard analysis showed that patients who received a transfusion in fact had a better survival, all factors being otherwise equal. An increased rate of transfused leukoreduced RBCs reported in this study (in which 76% of centers routinely used leukoreduced RBCs) could perhaps account for the differences between the earlier ABC study [3] (in which 46% of centers used leukodepleted blood most of the time) and the SOAP study [34]. It also is possible that transfusion thresholds have become so low that the benefits of blood transfusion outweigh the risks.

In patients with acute coronary syndrome, several studies have shown poorer outcomes, including increased mortality, in transfused groups compared with nontransfused patients after adjustment for potential confounders [21,35-37]; similar findings have been reported in patients who undergo percutaneous coronary interventions (PCI) [38]. However, although still controversial, RBC transfusions may be useful in subgroups of elderly patients with acute myocardial infarction [39] or patients with ST elevation myocardial infarction (STEMI) [21].

Patients who undergo cardiac surgery seem to have worse outcomes when transfused, including higher mortality [40,41], increased occurrence of postoperative infections [41,42], increased time on mechanical ventilation [40,43], and higher incidence of postoperative acute kidney injury [41,44].

Other studies have reported that trauma patients [45,46], including those with burns [47], may have increased mortality rates associated with receiving blood transfusions. In contrast, RBC transfusion has been reported to be associated with improved outcomes in patients with traumatic brain injury or subarachnoid hemorrhage [48,49]. In the early resuscitation of patients with severe sepsis, implementation of a therapeutic protocol that included RBC transfusion to obtain a hematocrit > 30% was associated with a significant reduction in hospital mortality [50].

These results should be interpreted with caution, because most of these data come from observational, retrospective studies, which are subject to numerous biases and sometimes control poorly for confounders, despite the use of various statistical tools, such as logistic regression [51]. It is clear that analyses should not include only admission data. For example, in a well-defined patient population, such as after cardiac surgery, patients who develop gastrointestinal bleeding and require a blood transfusion have a worse prognosis, which is not necessarily the result of the blood transfusion. It is of paramount importance that all risks factors are taken into account. Ruttinger et al. [52] illustrated this point very well. In a series of more than 3,000 surgical patients, these authors showed by using a limited multivariable analysis that transfusions were associated with a worse outcome, but a more complete analysis cancelled out this statistical observation.

Noninfectious serious hazards of transfusions
The reasons for the apparent worse outcome of transfused compared with nontransfused critically ill patients may be found in several detrimental effects of transfused blood, globally referred to under the acronym “Noninfectious Serious Hazards Of Transfusion” or NISHOT (Table 2) [53]. These include, among others, deleterious effects on the immune system (transfusion-related immunomodulation or “TRIM”) or on the cardiopulmonary system, e.g., transfusion-related acute lung injury (“TRALI”) [54] or transfusion-associated circulatory overload (“TACO”); the latter is currently the leading reported cause of transfusion-associated mortality [55]. These effects may be enhanced by pathologic conditions (e.g., sepsis) in which the microcirculation is impaired [56] and/or when the RBCs have been stored for some time.

Question of RBC storage
During storage, RBCs undergo a series of biological and biochemical changes collectively referred to as “the storage lesion” [57]. This includes intracellular changes (progressive depletion of 2,3-diphosphoglycerate [2,3-DPG] with increased affinity of hemoglobin for oxygen, depletion of ATP), membrane changes (membrane vesiculation, morphological changes eventually leading to irreversibly deformed spherochinocytes, lipid peroxidation and increased expression of phosphatidylserine, decreased deformability), and changes in the storage medium (decreased pH, increased potassium, release of proinflammatory cytokines). These stored RBCs also have an increased tendency to adhere to endothelium and could promote vasoconstriction; the stored RBCs act as a “sink” for nitric oxide [58]. Some animal studies [13] have shown deleterious effects of old RBCs on the microcirculation (potentially leading to tissue hypoxia and organ dysfunction). A human study found an inverse correlation between the age of transfused RBCs and maximal change in gastric mucosal pH, but these findings were challenged in subsequent studies [59-61].

The clinical consequences of storage lesions are still not clear. A recent review of the literature [57] identified 24 studies that address the effects of RBC length of storage on clinical (mortality, infections, length of stay, length of mechanical ventilation) or physiological (microcirculation, gastric mucosal pH) endpoints. Some studies found associations between the age of transfused
RBCs and poorer outcomes, whereas others did not. Overall, no clear detrimental effect of RBC age could be identified; however, definitive conclusions are difficult to obtain because of numerous statistical limitations and biases inherent to the study designs [51, 62]. Several, large, randomized, controlled trials in adult ICU and cardiac surgery patients are currently ongoing to address the clinical relevance of RBC storage. In the multicenter, double-blind prospective ABLE (Age of Blood Evaluation) study [63], adult patients admitted to the ICU are randomly assigned to receive leukoreduced RBCs stored for less than 7 days or issued according to standard procedure (expected average storage time of 19 days). The primary endpoint of this study is 90-day all-cause mortality. The target number of patients is 2,510 (for an expected improvement in primary endpoint greater than 5%) with an anticipated completion date by April 2013.

The RED Cell Storage Duration Study (RECESS) is a multicenter, randomized study in patients (age 12 years and older) who undergo complex cardiac surgery and are likely to require RBC transfusion [64]. Patients who need transfusion are randomized to receive RBCs stored for ≤ 10 days or ≥ 21 days. The primary endpoint of this study is the change in the Multiple Organ Dysfunction Score (MODS) from baseline to day 7, with secondary outcomes including all-cause 28-day mortality. The target number of patients is 1,832, and the anticipated completion date is September 2013.

The results of these trials, especially if older blood appears to be harmful, could have important logistic implications for blood banks [65, 66].

**Question of leukoreduction**

Many of the adverse effects associated with the transfusion of allogeneic RBCs have been shown to be related to the infusion of white blood cells (WBCs) present in the blood product. Leukoreduction is a process in which WBCs are reduced in number through centrifugation or filtration [67]. This process allows removal of approximately 99.995% of WBCs, but several thousand leukocytes (0.005% of a 500 ml blood unit) may still be present in the processed blood [67]; hence, the word “leukoreduction” is better than “deleukocytation.” The beneficial effects of this process include decreased

---

**Table 2 Selected infectious and non-infectious hazards of RBC transfusion in the ICU environment**

| Category                                      | Estimated frequency (event/no. of transfusions)* | Comment                                      |
|-----------------------------------------------|-------------------------------------------------|----------------------------------------------|
| **Infectious transmission** [89, 90]          |                                                 |                                              |
| HIV                                           | 1/2.3 \(10^6\)                                 |                                              |
| HBV                                           | 1/550000                                       |                                              |
| HCV                                           | 1/1.8 \(10^6\)                                 |                                              |
| HTLV 1/2                                      | 1/2 \(10^6\)                                   |                                              |
| Bacterial contamination                       | 1/14,000 to 1/28,000                           | GNB such as *Y. Enterocolitica* mostly encountered |
| **Noninfectious complications**               |                                                 |                                              |
| Immune-mediated [53, 89]                      |                                                 |                                              |
| Acute hemolytic transfusion reactions         | 1/10,000 to 1/50,000                           | Most frequently due to IgM, sometimes IgG    |
| Febrile nonhemolytic transfusion reactions    | 1/500                                           | Reduced incidence with prestorage leukoreduction |
| Anaphylactic reactions                        | 1/20,000 to 1/50,000                           | May be associated with IgA deficiency        |
| Transfusion-related acute lung injury (TRALI) | Highly variable (e.g., 1/29,000 [91], 1/46,700 [92], 1/172,000 [93] units transfused) | Must be differentiated from TACO             |
| Posttransfusion purpura                       | 1/143,000                                      | Rare; occurs 5-10 days after transfusion     |
| Transfusion-associated graft versus host disease | Rare (prevention by irradiation of blood products) | Mostly in immunocompromised hosts, poor prognosis |
| Nonimmune-mediated [89, 94]                   |                                                 |                                              |
| Incorrect blood component transfused (IBCT)   | 9.7/100,000 components                        | Remains frequent despite prevention strategies; must be differentiated from near-miss transfusion |
| Transfusion-associated circulatory overload (TACO) | Up to 1% of transfusions    | Major cause of transfusion-related death     |
| Hyperkalemia                                  |                                                 | Mainly after transfusion in newborns         |
| Hypocalcemia - hypothermia                    |                                                 | Mainly after massive transfusion             |
| Dilutional coagulopathy/thrombocytopenia      |                                                 | Mainly after massive transfusion             |

HIV human immunodeficiency virus; HBV hepatitis B virus; HCV hepatitis C virus; HTLV human T lymphotropic virus; GNB Gram-negative bacteria

*Frequencies may vary among studies and are only indicative
febrile nonhemolytic transfusion reactions, decreased transmission of certain pathogens, such as Epstein-Barr virus (EBV) or cytomegalovirus (CMV), parasites and prions [67], and possibly decreased lung injury, such as TRALI. Moreover, prestorage leukoreduction, in which WBC removal occurs before RBC storage, avoids the need for a leukodepletion filter during transfusion [67] (but a 170-200-μm filter still needs to be incorporated into the intravenous blood line).

In several studies, prestorage leukoreduction decreased RBC storage lesions, with fewer immunomodulating properties [68] and less adhesion of stored RBCs to the endothelium [69]. A clinical benefit of leukoreduction is still somewhat controversial, particularly in the critically ill patient where no randomized, controlled trial has been performed [70]. In a before-after study of 14,786 patients who underwent cardiac surgery, repair of hip fracture, or who required intensive care after surgery, there was a 1% decrease in mortality rate associated with the implementation of universal leukoreduction [71]. In a recent meta-analysis of nine RCTs involving 3,093 surgical patients, the use of leukoreduction significantly reduced the odds of postoperative infection (summary OR, 0.522; 95% CI, 0.332-0.821; \( p = 0.005 \)) [72]. This observation had been suggested in a previous meta-analysis [73] but has been challenged by another recent meta-analysis [74]. Nevertheless, leukoreduction makes sense, and many countries have adopted it as routine, even though costs are elevated. In Europe, at the time of the SOAP study in 2002, 76% of centers reported using leukodepleted blood routinely [34], whereas an earlier study performed in the same countries reported lower rates [3].

**The decision to transfuse**

Classically, the decision to transfuse is driven by arbitrary “triggers” (hemoglobin level) rather than clinical or physiologic findings. Data from the CRIT study [5], in which there was little evidence that age or comorbidities significantly influenced transfusion practice, tend to support this view.

Current recommendations for RBC transfusion [75,76] are mainly based on the famous “TRICC” (Transfusion Requirements In Critical Care) trial in which patients assigned to a restrictive transfusion strategy (transfusion if hemoglobin level < 7 g/dl) had similar 30-day mortality rates (and even lower mortality in subgroups with APACHE II < 20 and patients younger than age 55 years) than patients transfused according to a more liberal strategy (transfusion if hemoglobin level < 10 g/dl) [77]. In cardiac surgery patients, the recent randomized, monocenter “TRACS” (Transfusion Requirements after Cardiac Surgery) trial, which compared a restrictive to a liberal strategy (transfusion when hematocrit < 24% or < 30%, respectively), reported no difference in the primary endpoint (composite of 30-day mortality and morbidity [cardiogenic shock, ARDS, acute kidney injury]) between the groups [78].

However, it is quite clear there is no “magic” hemoglobin or hematocrit trigger, and for the same level of hemoglobin, some patients will do well, whereas others will not. Thus, the decision to transfuse a patient should be individualized, taking into account several factors, including signs and symptoms of tissue hypoxia (angina pectoris, cognitive dysfunction diagnosed by neuropsychological tests, or increased P300 latencies [79-81]), increased blood lactate levels [82], or electrocardiographic changes suggestive of myocardial ischemia.

Indirect measures of oxygenation, such as a decreased SvO2 or central venous oxygen saturation (ScvO2), also may be considered [82]. For example, in a study of early goal-directed therapy in patients with severe sepsis or septic shock admitted to an emergency department, a decrease in ScvO2 < 70% initiated a therapeutic intervention, including fluid resuscitation, inotropes, vasoressors, and RBC transfusion to increase hematocrit to > 30% [50]. Use of a decreased ratio of cardiac index to oxygen extraction (CI/O2 ratio) may be better, because this parameter also reflects the cardiac response to anemia [83].

**Economic aspects of blood transfusion**

The costs of blood transfusion are particularly complex to assess because of the many factors that have to be taken into consideration (blood collection and screening for pathogens; blood component processing, including leukoreduction, storage, transport to the transfusion facility; administration of blood to the patient; management of potential short- and long-term transfusion-related side effects) [84]. The subtype of the blood unit also may play a role because some products, such as CMV-negative or autologous units, are costlier than classical allogeneic RBCs. Consequently, studies in this field have given extremely varied results, which are not easily comparable.

Evidence has shown increased costs of RBC transfusion over time [85], related to various factors, including (but not limited to) use of leukoreduction and more sophisticated methods for pathogen detection, such as nucleic acid testing (NAT) [84]. For example, a study in Canada evaluated the mean societal cost of one allogeneic RBC unit at 264.81 US$, twice the cost estimated 7 years earlier [86]. Generally, these reported values are probably underestimated, and some have calculated that the cost of blood to society could in fact be twofold higher [84].

**Alternatives to blood transfusion**

Because of limited availability, costs and safety concerns related to blood transfusion, several strategies to reduce
blood transfusions can be considered in addition to increasing transfusion trigger thresholds. These include approaches to reduce blood losses, for example use of antifibrinolytic agents, such as tranexamic acid or epsilon-aminocaproic acid (EACA) and techniques of cell salvage during surgery; also, the use of small volume sample tubes can limit the blood losses related to sampling for laboratory studies. In a meta-analysis of 9 randomized controlled trials [87], subcutaneous administration of recombinant erythropoietin (EPO) in critically ill patients was shown to be associated with decreased transfusion rates, but this was not associated with improved mortality (except possibly in a subgroup of trauma patients [88]). Concerns also have been raised about potentially increased rates of deep vein thrombosis [88]. The development of artificial oxygen carriers is under investigation, but these have their own problems [89]. Further research is needed to improve these alternative strategies.

Conclusions
RBC transfusion can be lifesaving. During the past two decades, however, safety concerns have emerged, with suggestions that morbidity and mortality may be increased in patients who receive blood transfusions. Therefore, the decision to transfuse should be individualized, based on a rational approach and taking into account physiologic variables in addition to the hemoglobin value. This strategy, along with the use of alternatives whenever possible to limit bleeding, should limit unnecessary exposure to RBCs.

Authors’ contributions
CL drafted the manuscript. The manuscript was revised for intellectual content by JLV. Both authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 29 July 2011 Accepted: 4 October 2011 Published: 4 October 2011

References
1. Corwin HL, Surgenor SD, Gettinger A. Transfusion practice in the critically ill. Crit Care Med 2003, 31:5668-671.
2. Walsh TS, Lee RJ, Maciver CR, Gantoosh M, Mackirdy F, Binning AR, Cole S, McClelland DB. Anemia during and at discharge from intensive care: the impact of restrictive blood transfusion practice. Intensive Care Med 2006, 32:100-109.
3. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, Meier-Hellmann A, Nollet G, Perez-Bota D. Anemia and blood transfusion in critically ill patients. JAMA 2002, 288:1499-1507.
4. Nguyen BV, Bota DP, Melot C, Vincent JL. Time course of hemoglobin concentrations in nonbleeding intensive care unit patients. Crit Care Med 2003, 31:406-410.
5. Corwin HJ, Gettinger A, Pearle RG, Fink MP, Levy MM, Abraham E, Machtyyre NR, Shabot MM, Duh MS, Shapiro MJ. The CRIT Study: anemia and blood transfusion in the critically ill - Current clinical practice in the United States. Crit Care Med 2004, 32:S2-S2.
6. Rao MP, Boralessa H, Morgan C, Soni N, Goldhill DR, Brett SJ, Contreras M. Blood component use in critically ill patients. Anaesthesia 2002, 57:530-534.
7. Walsh TS, Gantoosh M, Maciver C, Lee RJ, Mackirdy F, McClelland DB, Kinsella J, Wallis C. Red cell requirements for intensive care units: adhering to evidence-based transfusion guidelines. Transfusion 2004, 44:1405-1411.
8. Westbrook A, Pettita V, Nichol A, Bailey MJ, Syres G, Murray L, Bellomo R, Wood E, Phillips LE, Street A, French C, Orford N, Santamaria J, Cooper DJ. Transfusion practice and guidelines in Australian and New Zealand intensive care units. Intensive Care Med 2010, 36:1138-1146.
9. Hsibert PC, Wells G, Martin C, Tweeddale M, Marshall J, Blajchman M, Pagliarello G, Sandham D, Schweitzer II, Bossevert D, Calder L. Variation in red cell transfusion practice in the intensive care unit: a multicentre cohort study. Crit Care 1999, 3:57-63.
10. French CJ, Bellomo R, Feiner SR, Lipman J, Chapman M, Boyce NW. Appropriateness of red blood cell transfusion in Australian intensive care practice. Med J Aust 2003, 177:548-551.
11. Scharle M, Fink MP. Red blood cell physiology in critical illness. Crit Care Med 2003, 31:651-657.
12. Pagnerelli M, Boudjelta KZ, Brohee D, Pino P, Carlier E, Vincent JL, Lejeune P, Vanhaevert M. Alterations of red blood cell shape and sialic acid membrane content in septic patients. Crit Care Med 2003, 31:2156-2162.
13. Raat NJ, Ince C. Oxygenating the microcirculation: the perspective from blood transfusion and blood storage. Vox Sang 2007, 93:12-18.
14. Fontana JL, Welbom L, Morgan PD, Sturm P, Martin G, Bunner R. Oxygen consumption and cardiovascular function in children during profound intraoperative nonvolemic hemodilution. Anesth Analg 1995, 80:219-225.
15. Zollinger A, Hager P, Singer T, Friedl HP, Pasch T, Sphdn DR. Extreme hemodilution due to massive blood loss in tumor surgery. Anesthesiology 1997, 87:985-987.
16. Leung JM, Weiskopf R, Feiner J, Hopf HW, Kelley S, Viele M, Lieberman J, Watson J, Nourani M, Pastor D, Yeap H, Ho R, Toy P. Electrocardiographic ST-segment changes during acute, severe isovolemic hemodilution in humans. Anesthesiology 2000, 93:1004-1010.
17. Weiskopf RB, Viele MK, Feiner J, Kelley S, Lieberman J, Noorani M, Leung JM, Fisher DM, Murray WR, Toy P, Moore MA. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998, 279:217-221.
18. Madjdpour C, Sphdn DR. Allogeneic red blood cell transfusion: physiology of oxygen transport. Best Pract Res Clin Anaesthesiol 2007, 21:163-171.
19. Levy PS, Kim SJ, Eckel PK, Chavez R, Ismail EF, Gould SA, Ramez Salem M, Crystal GJ. Limit to cardiac compensation during acute isovolemic hemodilution: influence of coronary stenosis. Am J Physiol 1995, 268:H340-349.
20. Kurek T, Lenarczyk R, Kowalczyk J, Swiatkowska A, Kowalski O, Stabryla-Deska J, Honisz G, Lekston A, Kalarus Z, Kukulska T. Effect of anemia in high-risk groups of patients with acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol 2010, 105:611-618.
21. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, Gibson CM, Braunwald E. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005, 111:2042-2049.
22. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 2005, 149:391-401.
23. Walsh TS, McClelland DB, Lee RJ, Gantoosh M, Maciver CR, MacFerlie A, Crofts SJ, Mellor I. Prevalence of ischemic heart disease at admission to intensive care and its influence on red cell transfusion thresholds: multicentre Scottish Study. Br J Anaesth 2003, 94:445-452.
24. Heibert PC, Ferguson DA, Stather D, Martin C, Doucette S, Blajchman M, Graham ID. Revisiting transfusion practices in critically ill patients. Crit Care Med 2005, 33:7-12.
25. Vincent JL, Pagnerelli M. Transfusion in the intensive care unit. Crit Care Med 2006, 34:596-598.
26. Timmouath A, Ferguson D, Yee K, Heibert PC. Clinical consequences of red cell storage in the critically ill. Transfusion 2006, 46:2014-2027.
27. English M, Ahmed M, Ngando C, Berkley J, Ross A. Blood transfusion for severe anaemia in children in a Kenyan hospital. Lancet 2002, 359:494-495.
28. Martini J, Carpenter B, Negrete AC, Frangos JA, Intaglietta M: Paradoxic hypotension following increased hematocrit and blood viscosity. Am J Physiol Heart Circ Physiol 2005, 289:H1236-2143.

29. Shah DM, Gottlieb ME, Rahim SS, Statton HH, Bari PS, Pakodi WH, Newell JC: Failure of red blood cell transfusion to increase oxygen transport or mixed venous PO2 in injured patients. J Trauma 1982, 22:741-746.

30. Creteur J, Neves AP, Vincent JL: Near-infrared spectroscopy technique to evaluate the effects of red blood cell transfusion on tissue oxygenation. Crit Care 2009, 13(Suppl 5):S11.

31. Faye A, Soysal P, Horn O, Habler C: Clinical evidence of blood transfusion effectiveness. Blood Transfus 2009, 7:250-258.

32. Mark PE, Convin HL: Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care 2008, 26:267-2674.

33. Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani DC: Allogeneic blood transfusion and postoperative outcome in elderly patients with acute myocardial infarction. Eur J Cardiothorac Surg 2005, 28:1608-1616.

34. Vincent JL, Sakr Y, Sprung C, Harboe S, Dams P: Are blood transfusions associated with greater mortality rates? Results of the Sepsis Occurrence in Acutely Ill Patients study. Anesthesiology 2008, 108:31-39.

35. Singla I, Zahid M, Good CB, Macaco A, Sonel AF: Impact of blood transfusions in patients presenting with anesthesia and suspected acute coronary syndrome. Am J Cardiol 2007, 99:1119-1212.

36. Yang X, Alexander KP, Chen AR, Roe MT, Brindis RG, Rao SV, Gliber WB, Ohman EM, Peterson ED: The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005, 45:1490-1495.

37. Rao SV, Jollis JG, Harrington RA, Williams P, Pothier L, Boyce PD, Christiani DC: Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med 2005, 33:1191-1198.

38. Vincent JL, Sakr Y, Sprung C, Harboe S, Damas P: Are blood transfusions associated with greater mortality rates? Results of the Sepsis Occurrence in Acutely Ill Patients study. Anesthesiology 2008, 108:31-39.

39. Young SN, Alexander KP, Chen AR, Roe MT, Brindis RG, Rao SV, Gliber WB, Ohman EM, Peterson ED: The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005, 45:1490-1495.

40. Mark PE, Convin HL: Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care 2008, 26:267-2674.

41. Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani DC: Allogeneic blood transfusion and postoperative outcome in elderly patients with acute myocardial infarction. Eur J Cardiothorac Surg 2005, 28:1608-1616.

42. Leal-Naval SR, Rinccon-Ferran MD, Garcia-Curell A, Hernuizo-Aviles A, Camacho-Larana P, Gamaaho-Montero J, Amaya-Villar R: Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. Chest 2001, 119:1461-1466.

43. Vamvakas EC, Carven JH: Allogeneic blood transfusion and postoperative duration of mechanical ventilation: effects of red cell supernatant, platelet supernatant, plasma components and total transfused fluid. Vox Sang 2002, 82:141-149.

44. Habib RH, Zacharias A, Schwann TA, Rondan CJ, Engoren M, Durham SJ, Shah A: Role of hemodilutional anemia and transfusion during cardiopulmonary bypass in renal injury after coronary revascularization: implications on operative outcome. Crit Care Med 2005, 33:1749-1756.

45. Maloney DL, Dunne J, Tracy JK, Putnam AT, Scalea TM, Napolitano LM: Blood transfusion, independent of shock severity, is associated with worse 30-day and 1-year mortality following coronary artery bypass surgery. Eur J Cardiovasc Prev Rehabil 2007, 14:17063-17068.

46. Mark PE, Sibbald WJ: Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1989, 269:3024-3029.

47. van de Watering L: Paradoxical hypotension following increased hematocrit and blood viscosity. Am J Respir Crit Care Med 2003, 168:17-21.

48. Sheridan RL, Faucler LD, Latenser BA, Gibran NS, Klein RL, Solem LD, Mozingo DW, Carpentier B, Negrete AC, Frangos JA, Intaglietta M: The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005, 45:1490-1495.

49. Mark PE, Sibbald WJ: Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993, 269:3024-3029.

50. van de Watering L: Paradoxical hypotension following increased hematocrit and blood viscosity. Am J Respir Crit Care Med 2003, 168:17-21.

51. van de Watering L: Paradoxical hypotension following increased hematocrit and blood viscosity. Am J Respir Crit Care Med 2003, 168:17-21.
71. Hebert PC, Ferguson D, Blachman MA, Wells GA, Kmetic A, Coyle D, Heddle N, Germain M, Goldman M, Toye B, Schwetzner J, vanWaalwegen C, Devine D, Sher GD. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003, 289:1941-1940.

72. Blumberg N, Zhao H, Wang H, Messing S, Heal JM, Lyman GH. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion 2007, 47:573-581.

73. Ferguson D, Khanna MP, Timmough A, Hebert PC. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Can J Anaesth 2004, 51:417-424.

74. Vamvakas EC. White-blood-cell-containing allogeneic blood transfusion and postoperative infection or mortality: an updated meta-analysis. Vox Sang 2007, 92:224-232.

75. Hebert PC, Timmough A, Conwin HL. Controversies in RBC transfusion in the critically ill. Curr Opin Anaesthesiol 2007, 20:515-526.

76. Dellinger RP, Levy MM, Carlet JM, Bion J, Bone RC, Brahimi N, Cerra FB, Dellinger EP, Gerlach H, Harvey M, Keh D, Kumar SP, Levy MS, Marshall J, Reinhart K, Stein C, Thompson BT, Trzeciak S, V柳en JS. International Sepsis Definitions Conference: sepsis and septic shock. Crit Care Med 2013, 41:965-983.

77. Hebert PC, Fergusson D, Khanna MP, Timmough A, Hebert PC. Controversies in RBC transfusion in the critically ill. Curr Opin Anaesthesiol 2007, 20:515-526.

78. Hajjar LA, Vincent JL, Galas FR, Nakamura RE, Silva CM, Santos MH, Ruotolo D, Tazerout M, Auler JO Jr, Dallan LO, Jatene FB, Fukushima J, Kalil Filho R, Sierra DB, Lopes NH, Mauad T, Roquim AC. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2010. Crit Care Med 2011, 39:128-153.

79. Weiskopf RB, Feiner J, Hopf H, Lieberman J, Finlay HE, Quah C, Kramer JH, Bostrom A, Toy P. Fresh blood and aged stored blood are equally efficacious in immediately reversing anemia-induced brain oxygenation deficits in humans. Anesthesiology 2006, 104:911-920.

80. Hare GM. Anaemia and the brain. Curr Opin Anaesthesiol 2004, 17:363-369.

81. Weiskopf RB, Kramer JH, Vamvakas EC, Auler JO Jr, Hopf H, Lieberman J, Finlay HE, Quah C, Kramer JH, Bostrom A, Toy P. Fresh blood and aged stored blood are equally efficacious in immediately reversing anemia-induced brain oxygenation deficits in humans. Anesthesiology 2006, 104:911-920.

82. MacDonald N, Scott JW, McCombie N, Robillard P, Gulivi A. Transfusion and risk of infection in Canada: Update 2006. Can J Infect Dis Med Microbiol 2006, 17:103-107.

83. Ozier Y, Muller JI, Mentes PM, Renaudier P, Aguilon P, Canivet N, Fabrigli P, Rebibo D, Tazerout M, Trophime L, Willaert B, Caldani C. Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008. Transfusion 2011, 51:735-739.

84. Shander A, Hofmann A, Gombotz H, Theusinger OM, Spahn DR. Venous oxygen saturation as a physiologic assessment of cardiac index in anemic patients. Chest 2000, 117:81-87.

85. Heddle N, Germain M, Goldman M, Toye B, Schwetzner J, vanWaalwegen C, Devine D, Sher GD. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003, 289:1941-1940.

86. Amin M, Fergusson D, Wilson K, Tinmough A, Aziz A, Coyle D, Hebert P. The cost of allogeneic red blood cells—a systematic review. Transfus Med 2003, 13:275-285.

87. Amin M, Fergusson D, Wilson K, Tinmough A, Aziz A, Coyle D, Hebert P. The societal unit cost of allogeneic red blood cells and red blood cell transfusion in Canada. Transfusion 2004, 44:1479-1486.

88. Zarychanski R, Turgeon AF, McIntyre L, Fergusson DA. Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ 2007, 177:257-274.

89. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klauser MA, Corwin MJ. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007, 357:965-976.

90. Timmough AT, McIntyre LA, Fowler RA. Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients. CMAJ 2008, 178:69-77.

91. Dodd RY. Current risk for transfusion transmitted infections. Curr Opin Hematol 2007, 14:671-676.

92. Stainsby D, Russell J, Cohen H, Lilleyman J. Reducing adverse events in blood transfusion. Br J Haematol 2005, 131:8-12.